Atom Investors’s Fate Therapeutics FATE Stock Holding History

Atom Investors’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-110,231	Closed	-$139K	–	655
2025 Q3	$139K	Buy	+110,231	New	+$119K	0.01%	533

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Atom Investors's FATE Position: Q4 2025 in Review

Atom Investors sold out of Fate Therapeutics (FATE) in Q4 2025, closing a stake of 110,231 shares — an estimated $139K sold.

Atom Investors first reported a position in FATE in Q3 2025 and held it in 1 quarter. The position peaked at $139K in Q3 2025. 146 funds tracked by Wall St. Rank hold FATE as of Q4 2025.

Atom Investors reported no remaining Fate Therapeutics position as of Q4 2025 after selling out during the quarter.
Atom Investors sold 110,231 Fate Therapeutics shares in Q4 2025, an estimated $139K.
Atom Investors first reported a position in Fate Therapeutics in Q3 2025 and held it in 1 quarter.
Atom Investors's Fate Therapeutics position peaked at $139K in Q3 2025.
146 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.